Schrödinger (SDGR): Could Shares Push Toward $40 After the Recent Rally?
Key Takeaways
- Schrödinger (SDGR) closed near $29.45 after a powerful rally that took shares roughly 140% higher over six months and pushed the stock to fresh 52-week highs.
- The $40 stock price target represents a meaningful move of roughly 35% above recent levels and sits well above the stock's current 52-week high near $31.59.
- The strongest bullish drivers are accelerating annual contract value (ACV) growth, a surprising return to quarterly profitability, and expanding partnerships with major pharmaceutical companies.
- The biggest obstacles are a stretched valuation relative to consensus analyst price targets — most of which sit below the current share price — and a drug-discovery pipeline still in early clinical stages.
- Key levels to watch: the $31.59 52-week high as near-term resistance, with psychological support in the low-to-mid $20s.
- Investors should view $40 as an ambitious but not impossible target that depends on continued software momentum and favorable pipeline news.
Why the $40 Level Stands Out
Schrödinger, Inc. (SDGR) combines a high-margin software platform with a clinical-stage drug-discovery pipeline. After trading near lows through much of 2024 and 2025, the stock rebounded sharply from a 52-week low around $10.94 to levels above $30. That recovery has naturally focused attention on whether the advance can extend to the round-number $40 mark.
Business Overview and Recent Results
The company reports results through two segments. Its Software segment licenses a computational platform that helps biopharmaceutical, materials-science, and academic users design molecules more efficiently. The Drug Discovery segment advances both proprietary and partnered programs. Full-year 2025 revenue reached approximately $255.9 million, up 23% from the prior year, while the net loss narrowed 45% to roughly $103.3 million.
Factors That Could Support Further Gains
Improving operating momentum provides the clearest case for higher prices. In the most recent quarter, Schrödinger posted a surprise profit of $0.08 per share against expectations of a loss, with revenue also exceeding forecasts. Annual contract value grew 27% year over year, and hosted software revenue rose to nearly half of total software revenue. Management expects ACV to expand another 10% to 15%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Partnership activity adds further support. Schrödinger has deepened ties with major pharmaceutical companies through its Bunsen AI co-scientist platform and enterprise informatics tools, and it co-founded Tectora Therapeutics with RA Capital and New Enterprise Associates. Its MALT1 inhibitor SGR-1505 received FDA Fast Track designation.
Valuation and Other Risks
Valuation remains the main constraint. After the rapid advance, shares now trade above the average analyst price target near $21, with the highest published target around $30. Reaching $40 would therefore require a move well beyond even the most optimistic published forecasts. The company continues to report consolidated losses and negative net margins while investing heavily in research. Its proprietary pipeline is still early-stage, and one program, SGR-2921, was discontinued in 2025. With a beta near 1.69, the stock tends to move more sharply than the broader market.
Technical Levels Worth Monitoring
The 52-week high near $31.59 is the key near-term resistance. A sustained break above that level would strengthen the uptrend. On the downside, the low-to-mid $20s mark a logical support zone based on recent consolidation. The $40 target sits well above prior highs, so any move toward it would need fresh buying interest rather than a simple retest of old levels. From what I see, these technical markers help frame realistic expectations around the $40 discussion.
Final Assessment
A push toward $40 for Schrödinger appears ambitious yet plausible over a longer horizon if software ACV continues to accelerate, hosted-software adoption grows, and pipeline updates remain favorable. At the same time, the stock already exceeds consensus price targets, the company is not yet profitable on an annual basis, and clinical programs carry inherent binary risks. I’m watching this closely for signs that momentum can be sustained above recent highs.
Tracking Momentum With AI Daily Buy/Sell Signals
For investors following names like Schrödinger, Tickeron’s AI Daily Buy/Sell Signals provide a useful way to monitor changing conditions. The tool applies artificial intelligence to thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical patterns and market behavior. In my view, these signals offer a practical complement to traditional analysis when evaluating whether momentum in a name like SDGR is likely to persist.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SDGR turns positive, indicating new upward trend
SDGR saw its Momentum Indicator move above the 0 level on September 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 77 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SDGR just turned positive on September 15, 2026. Looking at past instances where SDGR's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDGR advanced for three days, in 213 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 136 of 173 cases where SDGR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for SDGR moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 60 cases where SDGR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
SDGR broke above its upper Bollinger Band on September 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SDGR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.707) is normal, around the industry mean (7.432). P/E Ratio (46.778) is within average values for comparable stocks, (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (6.835) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SDGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of chemical simulation software solutions to pharmaceutical industry.
Industry ServicestotheHealthIndustry
Advertisement